Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac021 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yoshiya Tanaka und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To determine the efficacy of peficitinib in reducing joint damage and predictive factors affecting treatment response in Japanese patients with rheumatoid arthritis.
Methods
This post hoc analysis used data from a placebo-controlled, phase 3 trial (RAJ4) of peficitinib in patients with rheumatoid arthritis and inadequate response to methotrexate. Erosion and joint space narrowing (JSN) were assessed at baseline and at Week 28/early termination of treatment using the van der Heijde-modified Sharp method. A univariate logistic regression analysis of change from baseline in a modified total Sharp score identified predictive factors with significant treatment interaction; the effects of these factors on treatment response were further evaluated using a multivariate model.
Results
The analyses included 481 patients. For most joint groups, peficitinib demonstrated a reduced change from baseline at Week 28/early termination in erosion and JSN scores versus placebo; a numerically greater effect was observed with peficitinib 150 mg versus 100 mg. Baseline C-reactive protein (CRP) and prednisolone dose were identified as clinically significant negative predictive factors: the treatment effect decreased as CRP or prednisolone dose increased for both peficitinib doses.
Conclusions
Peficitinib 100 mg and 150 mg reduced joint damage versus placebo, across almost all joint groups. Higher baseline CRP and/or prednisolone dose were associated with reduced peficitinib efficacy. ClinicalTrials.gov identifier NCT02305849
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Corporate Strategy Department, Astellas Pharma Inc., Tokyo, Japan.
- Biostatistics Group, Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
- Astellas Pharma Inc., Tokyo, Japan.
- Japan-Asia Clinical Development 1, Development, Astellas Pharma Inc., Tokyo, Japan.
ORCID-Profile: Yoshiya Tanaka, Mitsuhiro Rokuda
Zitieren
APA
Tanaka, Y., Takeuchi, T., Kato, D., Kaneko, Y., Fukuda, M., Izutsu, H., Rokuda, M., & van der Heijde, D. (2023). Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology. https://doi.org/10.1093/mr/roac021
Vancouver
Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, et al. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology. 2023. doi:10.1093/mr/roac021
BibTeX
@article{Tanaka2023,
author = {Tanaka, Yoshiya and Takeuchi, Tsutomu and Kato, Daisuke and Kaneko, Yuichiro and Fukuda, Musashi and Izutsu, Hiroyuki and Rokuda, Mitsuhiro and van der Heijde, Désirée},
title = {Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac021}
}
EUVIMED